Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to cut risky pills for seniors with arthritis

NCT ID NCT07278609

Knowledge-focused Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a doctor's computer tool (MedSafer) and patient brochures (EMPOWER) can help reduce the use of potentially harmful medications in adults aged 60 and older with rheumatic diseases who take five or more regular drugs. Researchers will follow 100 participants for 18-20 months, comparing medication changes before and after introducing these tools. The goal is to improve medication safety without affecting quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MedSafer deprescribing reports and EMPOWER brochures
What this could lead to
If successful, this could provide a simple way to reduce unnecessary or risky medications in older adults with rheumatic conditions, improving safety without harming quality of life.
What could go wrong
This is a small, early-stage observational study, not a large trial. The results may not apply to all patients, and deprescribing might not always be safe or acceptable to doctors or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be recruited from patients attending usual follow-up care for chronic rheumatic diseases at the McGill University Health Centre

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥60 * Followed by a rheumatologist at MUHC for an inflammatory arthritis (such as rheumatoid arthritis, psoriatic arthritis, spondyloarthritis), a systemic autoimmune rheumatic disease (such as systemic lupus erythematosus, inflammatory myositis, systemic sclerosis, antiphospholipid antibody syndrome, Sjogren syndrome, systemic vasculitis), or another chronic musculoskeletal or rheumatic condition (such as crystal arthritis and osteoarthritis) * Currently taking ≥5 regular medications and ≥1 PIM * Anticipated ongoing clinical follow-up in rheumatology at an interval of every 3-9 months Exclusion Criteria: * Unable to provide informed consent * Acute life-threatening illness or life expectancy \<12 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antiphospholipid antibody syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy antiphospholipid syndrome arthritic joint disease autoimmune disease crystal arthropathy musculoskeletal system disorder osteoarthritis psoriatic arthritis rheumatic disorder rheumatoid arthritis Sjogren syndrome spondyloarthropathy systemic lupus erythematosus systemic sclerosis vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Inflammatory arthritis Muskuloskeletal diseases Rheumatic diseases Systemic autoimmune diseases Systemic lupus erthematosus (SLE) Vasculitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Montreal General Hospital, McGill University Health Centre

    RECRUITING

    Montreal, Quebec, H3G1A4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.